OmniAb Insider Trades Show Routine RSU Vesting, Not a Market Signal ?

Insider Activity Highlights a Routine RSU Vesting Cycle

On April 7 2026, OmniAb’s Chief Legal Officer, Charles Berkman, recorded a series of transactions that are largely consistent with the company’s scheduled restricted‑stock‑unit (RSU) vesting plan. The filings show a $0 purchase of 13,542 shares (price $0.00) and a sell‑to‑cover of 7,157 shares at $1.49, the latter covering the tax withholding required when the RSUs vest. In addition, Berkman sold 13,542 restricted‑stock‑units, a move that simply reflects the conversion of those units into common stock. The net result is a modest increase in his overall holdings—from 399,085 to 406,242 shares—after the vesting event.

What Investors Should Take Away

The transaction pattern is typical of a corporate equity incentive program rather than a signal of market sentiment. The price paid or received is largely a function of the current market level ($1.51) and the statutory tax withholding. The fact that the share count is still below the 52‑week high suggests the stock remains in a downtrend, but the routine nature of the trade indicates no immediate change in insiders’ confidence. For shareholders, the key takeaway is that the company’s insiders are staying invested and following the established incentive schedule, which can be reassuring in a volatile biotech environment.

Berkman’s Historical Trading Profile

Charles Berkman’s transaction history over the past six months shows a pattern of buying common stock and RSUs during vesting dates, coupled with sell‑to‑cover sales that match the tax obligations. He has not engaged in large discretionary sales, and his holdings have steadily increased from 64,584 shares (post‑Feb 18) to 406,242 shares (post‑April 7). His trades are executed through the same brokerage (Morgan Stanley Smith Barney) as other senior executives, indicating alignment with company policy. The absence of significant short‑term gains or losses suggests that Berkman is not using insider information to time the market, but rather following the structured equity plan.

Context Within Broader Insider Activity

Across OmniAb’s senior management, similar patterns emerge. The President and CEO, Matthew Foehr, and the Executive VP, Finance and CFO, Kurt Gustafson, are also buying and selling shares primarily to cover tax withholdings and to exercise RSU grants. The volume of insider transactions on April 7—together with the social‑media sentiment of +10 and a buzz of 11 %—does not indicate a sudden shift in confidence or a strategic re‑allocation of capital. Instead, the market activity reflects the routine execution of a multi‑year incentive plan that is designed to align executive interests with long‑term shareholder value.

Implications for OmniAb’s Future

For investors, the takeaway is that insiders remain committed to the company’s trajectory. The incremental increase in Berkman’s stake, coupled with the broader team’s continued investment, signals a shared belief in OmniAb’s antibody‑discovery platform. While the stock has declined 18.6 % year‑to‑date and sits near its 52‑week low, the disciplined insider trading suggests that management is not seeking a quick turnaround but is instead focused on long‑term innovation milestones. As such, investors who are comfortable with the biotech cycle may view this period as an opportune moment to assess the company’s pipeline and valuation in a more patient, fundamentals‑driven context.